Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura

Detalhes bibliográficos
Autor(a) principal: Lissi, Cristian Bianchi
Data de Publicação: 2023
Outros Autores: Zanetti, Maria Olívia Barboza
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/40605
Resumo: In parallel with population aging and contemporary lifestyle, the incidence of individuals living with Type 2 Diabetes Mellitus (T2DM) is increasing, making it one of the main causes of morbidity and mortality in the world. In order to make a more assertive and individualized therapeutic choice and avoid micro and macrovascular complications secondary to T2DM, it is essential that health professionals are aware of all available pharmacotherapeutic resources. This work is a narrative review with the objective of discussing the particularities of the therapeutic options currently available for the management of T2DM. Books, clinical protocols, therapeutic guidelines and academic articles available in Scielo and Google academic databases were searched, considering works written in Portuguese or English. The search was performed in October 2022. The results reinforce that the importance of glycemic control to reduce the risk of complications is widely recognized by current therapeutic protocols and favor the adoption of evidence-based clinical approaches. There are many therapeutic options with demonstrated efficacy in achieving therapeutic goals, the main pharmacological classes are: biguanides, glitazones, sulfonylureas, glinides, alpha-glucosidase inhibitors, insulins, DDP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors. Treatment options, however, need to be individualized according to clinical characteristics (risk of hypoglycemia, age, comorbidities, disease stage, T2DM complications, tolerability and adverse effects), sociodemographic characteristics, preferences and individual values, favoring the person-centered care.
id UNIFEI_a75fd83281c6194208c5cc34429edeea
oai_identifier_str oai:ojs.pkp.sfu.ca:article/40605
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literaturaPharmacotherapeutic options for the management of Type 2 Diabetes Mellitus: literature reviewOpciones farmacoterapéuticas para el manejo de la Diabetes Mellitus tipo 2: revisión de la literaturaDiabetes Mellitus Tipo 2HipoglucemiantesTerapia farmacológicaRevisión.Diabetes Mellitus Tipo 2HipoglicemiantesTratamento farmacológicoRevisão.Diabetes Mellitus, Type 2Hypoglycemic agentsDrug therapyReview.In parallel with population aging and contemporary lifestyle, the incidence of individuals living with Type 2 Diabetes Mellitus (T2DM) is increasing, making it one of the main causes of morbidity and mortality in the world. In order to make a more assertive and individualized therapeutic choice and avoid micro and macrovascular complications secondary to T2DM, it is essential that health professionals are aware of all available pharmacotherapeutic resources. This work is a narrative review with the objective of discussing the particularities of the therapeutic options currently available for the management of T2DM. Books, clinical protocols, therapeutic guidelines and academic articles available in Scielo and Google academic databases were searched, considering works written in Portuguese or English. The search was performed in October 2022. The results reinforce that the importance of glycemic control to reduce the risk of complications is widely recognized by current therapeutic protocols and favor the adoption of evidence-based clinical approaches. There are many therapeutic options with demonstrated efficacy in achieving therapeutic goals, the main pharmacological classes are: biguanides, glitazones, sulfonylureas, glinides, alpha-glucosidase inhibitors, insulins, DDP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors. Treatment options, however, need to be individualized according to clinical characteristics (risk of hypoglycemia, age, comorbidities, disease stage, T2DM complications, tolerability and adverse effects), sociodemographic characteristics, preferences and individual values, favoring the person-centered care.Paralelamente al envejecimiento de la población y al estilo de vida contemporáneo, la incidencia de individuos que viven con Diabetes Mellitus Tipo 2 (DM2) va en aumento, convirtiéndola en una de las principales causas de morbilidad y mortalidad en el mundo. Para realizar una elección terapéutica más asertiva, individualizada y evitar complicaciones micro y macrovasculares secundarias a la DM2, es fundamental que los profesionales sanitarios conozcan y dominen todos los recursos farmacoterapéuticos disponibles. Este trabajo es una revisión narrativa con el objetivo de discutir las particularidades de las opciones terapéuticas actualmente disponibles para el manejo de la DM2. Se realizaron búsquedas en libros, protocolos clínicos y guías terapéuticas y artículos académicos disponibles en las bases de datos Scielo y Google académico, considerando los trabajos escritos en portugués o inglés. La búsqueda se realizó en octubre de 2022. Los resultados refuerzan que la importancia del control glucémico para reducir el riesgo de complicaciones es ampliamente reconocida por los protocolos terapéuticos actuales y favorecen la adopción de prácticas clínicas basadas en evidencia. Existen muchas opciones terapéuticas con eficacia demostrada en la consecución de objetivos terapéuticos, siendo las principales clases farmacológicas: biguanidas, glitazonas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, insulinas, inhibidores de DDP-4, agonistas de GLP-1 e inhibidores de SGLT2. Las opciones de tratamiento, sin embargo, necesitan individualizarse según características clínicas (riesgo de hipoglucemia, edad, comorbilidades, estadio de la enfermedad, complicaciones de la DM2, tolerabilidad y efectos adversos), características sociodemográficas, preferencias y valores del individuo, favoreciendo la prestación atención centrada en la persona.Em paralelo ao envelhecimento populacional e ao estilo de vida contemporâneo, a incidência de indivíduos vivendo com Diabetes Mellitus tipo 2 (DM2) é crescente, tornando-a uma das principais causas de morbimortalidade no mundo. Para realizar uma escolha terapêutica mais assertiva, individualizada e evitar as complicações micro e macrovasculares secundárias ao DM2, é fundamental que os profissionais de saúde conheçam e dominem todos os recursos farmacoterapêuticos disponíveis. Este trabalho trata-se de uma revisão narrativa com o objetivo de discutir as particularidades das opções terapêuticas atualmente disponíveis para o manejo do DM2.  Foram pesquisados livros, protocolos clínicos e diretrizes terapêuticas e artigos acadêmicos disponíveis nas bases de dados Scielo e Google acadêmico, considerando os trabalhos redigidos em idioma português ou inglês. A busca foi realizada em outubro de 2022. Os resultados reforçam que a importância do controle glicêmico para reduzir o risco de complicações é amplamente reconhecida pelos protocolos terapêuticos e diretrizes clínicas vigentes e favorecem a adoção de condutas clínicas baseadas em evidências. Existem muitas opções terapêuticas com eficácia demonstrada no alcance das metas terapêuticas, sendo as principais classes farmacológicas: biguanidas, glitazonas, sulfonilureias, glinidas, inibidores de alfa-glicosidase, insulinas, inibidores de DDP-4, agonistas de GLP-1 e inibidores de SGLT2. As opções de tratamento, no entanto, precisam ser individualizadas de acordo com as características clínicas (risco de hipoglicemia, idade, comorbidades, estágio da doença, complicações do DM2, tolerabilidade e efeitos adversos), sociodemográficas, preferências e valores do indivíduo, favorecendo a prestação de cuidados centrados na pessoa. Research, Society and Development2023-03-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4060510.33448/rsd-v12i3.40605Research, Society and Development; Vol. 12 No. 3; e15112340605Research, Society and Development; Vol. 12 Núm. 3; e15112340605Research, Society and Development; v. 12 n. 3; e151123406052525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/40605/33138Copyright (c) 2023 Cristian Bianchi Lissi; Maria Olívia Barboza Zanettihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessLissi, Cristian Bianchi Zanetti, Maria Olívia Barboza 2023-03-23T08:33:38Zoai:ojs.pkp.sfu.ca:article/40605Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2023-03-23T08:33:38Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
Pharmacotherapeutic options for the management of Type 2 Diabetes Mellitus: literature review
Opciones farmacoterapéuticas para el manejo de la Diabetes Mellitus tipo 2: revisión de la literatura
title Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
spellingShingle Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
Lissi, Cristian Bianchi
Diabetes Mellitus Tipo 2
Hipoglucemiantes
Terapia farmacológica
Revisión.
Diabetes Mellitus Tipo 2
Hipoglicemiantes
Tratamento farmacológico
Revisão.
Diabetes Mellitus, Type 2
Hypoglycemic agents
Drug therapy
Review.
title_short Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
title_full Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
title_fullStr Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
title_full_unstemmed Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
title_sort Opções farmacoterapêuticas para o manejo do Diabetes Mellitus Tipo 2: revisão da literatura
author Lissi, Cristian Bianchi
author_facet Lissi, Cristian Bianchi
Zanetti, Maria Olívia Barboza
author_role author
author2 Zanetti, Maria Olívia Barboza
author2_role author
dc.contributor.author.fl_str_mv Lissi, Cristian Bianchi
Zanetti, Maria Olívia Barboza
dc.subject.por.fl_str_mv Diabetes Mellitus Tipo 2
Hipoglucemiantes
Terapia farmacológica
Revisión.
Diabetes Mellitus Tipo 2
Hipoglicemiantes
Tratamento farmacológico
Revisão.
Diabetes Mellitus, Type 2
Hypoglycemic agents
Drug therapy
Review.
topic Diabetes Mellitus Tipo 2
Hipoglucemiantes
Terapia farmacológica
Revisión.
Diabetes Mellitus Tipo 2
Hipoglicemiantes
Tratamento farmacológico
Revisão.
Diabetes Mellitus, Type 2
Hypoglycemic agents
Drug therapy
Review.
description In parallel with population aging and contemporary lifestyle, the incidence of individuals living with Type 2 Diabetes Mellitus (T2DM) is increasing, making it one of the main causes of morbidity and mortality in the world. In order to make a more assertive and individualized therapeutic choice and avoid micro and macrovascular complications secondary to T2DM, it is essential that health professionals are aware of all available pharmacotherapeutic resources. This work is a narrative review with the objective of discussing the particularities of the therapeutic options currently available for the management of T2DM. Books, clinical protocols, therapeutic guidelines and academic articles available in Scielo and Google academic databases were searched, considering works written in Portuguese or English. The search was performed in October 2022. The results reinforce that the importance of glycemic control to reduce the risk of complications is widely recognized by current therapeutic protocols and favor the adoption of evidence-based clinical approaches. There are many therapeutic options with demonstrated efficacy in achieving therapeutic goals, the main pharmacological classes are: biguanides, glitazones, sulfonylureas, glinides, alpha-glucosidase inhibitors, insulins, DDP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors. Treatment options, however, need to be individualized according to clinical characteristics (risk of hypoglycemia, age, comorbidities, disease stage, T2DM complications, tolerability and adverse effects), sociodemographic characteristics, preferences and individual values, favoring the person-centered care.
publishDate 2023
dc.date.none.fl_str_mv 2023-03-04
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/40605
10.33448/rsd-v12i3.40605
url https://rsdjournal.org/index.php/rsd/article/view/40605
identifier_str_mv 10.33448/rsd-v12i3.40605
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/40605/33138
dc.rights.driver.fl_str_mv Copyright (c) 2023 Cristian Bianchi Lissi; Maria Olívia Barboza Zanetti
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Cristian Bianchi Lissi; Maria Olívia Barboza Zanetti
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 12 No. 3; e15112340605
Research, Society and Development; Vol. 12 Núm. 3; e15112340605
Research, Society and Development; v. 12 n. 3; e15112340605
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052619813814272

Registros relacionados